Electrostatic interactions of monoclonal antibodies with subcutaneous tissue

Therapeutic Delivery

Volumn 2, Issue 6, 2011, Pages 727-736

  MacH, Henryk ^a   Gregory, Sonia M ^a   MacKiewicz, Alexis ^a   Mittal, Sarita ^a   Lalloo, Anita ^a   Kirchmeier, Marc ^a   Shameem, Mohammed ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1; MONOCLONAL ANTIBODY 2; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG INTERACTION; DRUG TISSUE LEVEL; EX VIVO STUDY; IONIC STRENGTH; NONHUMAN; PH; PRIORITY JOURNAL; RAT; STATIC ELECTRICITY; SUBCUTANEOUS TISSUE; TISSUE HOMOGENATE; TISSUE INTERACTION;

EID: 79960226695     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.31     Document Type: Article

References (42)

1. Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 93(6) 1390-1402 (2004) (Pubitemid 38725014)
2. Arakawa T, Timasheff SN. Theory of protein solubility. Methods Enzymol. 114, 49-77 (1985)
3. Schein C. Solubility as a function of protein structure and solvent components. Biotechnol. Bioeng. 8, 308-317 (1990)
4. Mahler H-C, Mueller R, Friess W, Delille A, Matheus S. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur. J. Pharm. Biopharm. 59(3), 407-417 (2005) (Pubitemid 40342515)
5. Bajaj H, Sharma VK, Badkar A, Zeng D, Nema S, Kalonia DS. Protein structural conformation and not second virial coefficient relates to long-term irreversible aggregation of a monoclonal antibody and ovalbumin in solution. Pharm. Res. 23(6), 1382-1394 (2006) (Pubitemid 43946160)
6. Sukumar M, Doyle BL, Combs JL, Pekar AH. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm. Res. 21(7), 1087-1093 (2004) (Pubitemid 38954191)
7. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm. Res. 27(4), 544-575 (2010)
8. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10(4), 307-377 (1993) (Pubitemid 24021947)
9. Volkin DB, Mach H, Middaugh CR. Degradative covalent reactions important to protein stability. Mol. Biotechnol. 8(2), 105-122 (1997) (Pubitemid 127498446)
10. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 7(2), 167-169 (1990) (Pubitemid 20208069)
11. Charman SA, Segrave AM, Edwards GA, Porter CJ. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J. Pharm. Sci. 89(2), 168-177 (2005) (Pubitemid 30120797)
12. Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci. 89(3), 297-310 (2000) (Pubitemid 30152431)
13. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 13(9), 923-954 (1990) (Pubitemid 20260734)
14. Fernqvist E, Linde B, Ostman J, Gunnarsson R. Effects of physical exercise on insulin absorption in insulin-dependent diabetics. A comparison between human and porcine insulin. Clin. Physiol. 6(6), 489-497 (1986)
15. Linde B. Dissociation of insulin absorption and blood flow during massage of a subcutaneous injection site. Diabetes Care 9(6), 570-574 (1986) (Pubitemid 17208934)
16. Hildebrandt P, Sestoft L, Nielsen SL. The absorption of subcutaneously injected short-acting soluble insulin: influence of injection technique and concentration. Diabetes Care 6(5), 459-462 (1983) (Pubitemid 13005552)
17. Xu Z, Wang Q, Zhuang Y et al. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J. Clin. Pharmacol. 50(3), 276-284 (2010)
18. Shire SJ, Liu JJ. Development of high protein concentration pharmaceuticals for SC delivery: fitting all the pieces together. Abstracts of Papers: 239th ACS National Meeting. San Francisco, CA, USA, 25 January 2010
19. Mach H, Sanyal G, Volkin DB, Middaugh CR. Applications of ultraviolet absorption spectroscopy to the analysis of biopharmaceuticals. In:Therapeutic Protein and Peptide Formulation and Delivery (Volume 675). Shahrokh Z, Sluzky V, Cleland JL, Shire SJ, Randolph TW (Eds). American Chemical Society Symposium Series, DC, USA (1997)
20. Mach H, Middaugh CR. Ultraviolet Spectroscopy as a tool in therapeutic protein development. J. Pharm. Sci. 100(4) 1214-1227 (2011)
21. Al-Shakhshir R, Regnier F, White JL, Hem SL. Effect of protein adsorption on the surface charge characteristics of aluminum-containing adjuvants. Vaccine 12(5), 472-474 (1994) (Pubitemid 24107587)
22. von Smoluchowski M. Bull. Int. Acad. Sci. Cracovie, 184 (1903)
23. Chiou S-H, Wu S-H. Evaluation of commonly used electrophoretic methods for the analysis of proteins and peptides and their application to biotechnology. Anal. Chim. Acta 383(1-2), 47-60 (1999) (Pubitemid 29097660)
24. Li D, Fu S, Lucy CA. Prediction of electrophoretic mobilities. 3. Effect of ionic strength in capillary zone electrophoresis. Anal. Chem. 71(3), 687-699 (1999)
25. Schubert S, Freitag R. Investigation of the interaction mechanism of the recombinant human antibody MDJ8 and its fragments with chromatographic apatite phases. J. Chromatogr. A 1216(18), 3831-3840 (2009)
26. Daitoku D, Kurose T, Mori E, Hashimoto M, Kawamata S. Changes in the rat subcutaneous connective tissue after saline and histamine injection in relation to fluid storage and excretion. Arch. Histol. Cytol. 70(1), 29-41 (2007) (Pubitemid 46917491)
27. Ahamed T, Nfor BK, Verhaert PDEM et al. pH-gradient ion-exchange chromatography: an analytical tool for design and optimization of protein separations. J. Chromatogr. A 1164(1-2), 181-188 (2007) (Pubitemid 47284107)
28. Lichtenbelt JWT, Heuvelsland WJM, Oldenzeel ME, Zsom RLJ. Adsorption and immunoreactivity of proteins on polystyrene and on silica. Competition with surfactants. Colloids Surf. B 1(2), 75-82 (1993)
29. Norde W, Favier JP. Structure of adsorbed and desorbed proteins. Colloids Surf. 64(1), 87-93 (1992)
30. Bookbinder LH, Hofer A, Haller MF et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J. Control. Release 114(2), 230-241 (2006) (Pubitemid 44291844)
31. Seki K, Yamane Y, Shinoura A et al. Experimental and clinical study on the lymph circulation. Am. Heart J. 75(5), 620-629 (1968)
32. Skutelsky E, Rudich Z, Danon D. Surface charge properties of the luminal front of blood vessel walls: an electron microscopical analysis. Thromb. Res. 7(4), 623-634 (1975)
33. Rozhkova A. Quantitative analysis of monclonal antibody by cation-exchange chromatofocusing. J. Chromatogr. A 1216, 5989-5994 (2009)
34. Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99(17), 11393-11398 (2002) (Pubitemid 34920936)
35. Wang W, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharm. Therapeutics 84, 548-558 (2008)
36. Waldmann TA, Strober W. Metabolism of immunoglobulins. Progr. Allergy 13, 1-110 (1969)
37. Junghans RP. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol. Res. 16(1), 29-57 (1997)
38. Humira®. Prescribing information www.rxabbott.com/u4-prescribing- info.cfm
39. Raptiva®. Prescribing information www.gene.com/gene/products/ information/pdf/raptiva-prescribing.pdf
40. Xolair®. Prescribing information www.xolair.com/prescribing- information. html
41. Humalog®. Prescribing information http://pi.lilly.com/us/humalog7525- pi.pdf
42. Lantus®. Prescribing information www.products.sanofi-aventis.us/ lantus/lantus.html